Vivani Medical, Inc. - Common Stock (VANI)
1.0600
0.00 (0.00%)
Vivani Medical, Inc. is a biotechnology company focused on developing innovative drug delivery solutions to improve patient outcomes in chronic disease management
The company's primary expertise lies in the creation of miniaturized implantable devices that provide sustained release of therapeutic agents over extended periods. By enhancing the delivery of medications for conditions such as diabetes and obesity, Vivani aims to offer safer, more effective alternatives to traditional treatment methods, thereby transforming the way patients manage their health. The commitment to advancing medical technology drives Vivani's research and development endeavors, with a vision to make a meaningful impact on healthcare.
Previous Close | 1.060 |
---|---|
Open | - |
Bid | 1.050 |
Ask | 1.080 |
Day's Range | N/A - N/A |
52 Week Range | 1.030 - 2.220 |
Volume | 305 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 75,999 |
News & Press Releases

Vivani Medical, Inc. (NASDAQVANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step toward addressing one of healthcare’s most pressing challenges: medication adherence in metabolic diseases including chronic weight management and type 2 diabetes. The Company also announced full enrollment in the LIBERATE-1 study, which was achieved in just four weeks after enrollment of the first subject, signaling early potential interest for this six-month, subdermal GLP-1 implant and reaffirming previous estimates that top-line results should be available in mid-2025.
By Vivani Medical, Inc. · Via Business Wire · March 13, 2025

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.
Via Benzinga · March 13, 2025

Vivani Medical, Inc. (NASDAQVANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise.
By Vivani Medical, Inc. · Via Business Wire · March 12, 2025

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.
Via Benzinga · March 12, 2025

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.
By Vivani Medical, Inc. · Via Business Wire · December 19, 2024

Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.
Via Benzinga · December 19, 2024

Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024.
By Vivani Medical, Inc. · Via Business Wire · December 4, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
By Vivani Medical, Inc. · Via Business Wire · November 13, 2024

Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference, taking place in New York on October 30, 2024.
By Vivani Medical, Inc. · Via Business Wire · October 22, 2024

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected by 2025.
Via Benzinga · September 26, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in Australia has formally acknowledged a first in human clinical trial of the Company’s miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. This clinical trial, known as LIBERATE-1™, will investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant and represents the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.
By Vivani Medical, Inc. · Via Business Wire · September 26, 2024

Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.
By Vivani Medical, Inc. · Via Business Wire · September 23, 2024

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is set to begin in Q4 2024.
Via Benzinga · September 4, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive preclinical liver fat results with its exenatide implant.
By Vivani Medical, Inc. · Via Business Wire · September 4, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York.
By Vivani Medical, Inc. · Via Business Wire · August 28, 2024

VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.
By Vivani Medical, Inc. · Via Business Wire · August 13, 2024

Via Benzinga · August 5, 2024

Via Benzinga · August 2, 2024

Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or overweight patients. The trial includes comparisons with semaglutide and exenatide injections.
Via Benzinga · July 11, 2024

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced that it expects to initiate the first clinical study in the NPM-115 program in the fourth quarter of 2024 in Australia, pending regulatory clearance in that country. The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.
By Vivani Medical, Inc. · Via Business Wire · July 11, 2024

Via Benzinga · June 13, 2024

Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.
Via Benzinga · June 13, 2024

Via Benzinga · June 13, 2024

Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.
Via Benzinga · June 13, 2024